|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2008-8-26
|
|
pubmed:abstractText |
gamma9delta2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T gammadelta can be selectively expanded in vivo with BrHPP (IPH1101, Phosphostim) and interleukin 2 (IL-2). A phase I Study was conducted in patients with metastatic renal cell carcinoma (mRCC) to determine the maximum-tolerated dose and safety of Innacell gammadelta, an autologous cell-therapy product based on gamma9delta2 T lymphocytes, in patients with mRCC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0340-7004
|
|
pubmed:author |
pubmed-author:AudrainMarieM,
pubmed-author:BennounaJaafarJ,
pubmed-author:BompasEmmanuelleE,
pubmed-author:GaléaCélineC,
pubmed-author:Lafaye-de MicheauxSylvieS,
pubmed-author:NégrierSylvieS,
pubmed-author:NeidhardtEve MarieEM,
pubmed-author:PhilipIrèneI,
pubmed-author:RimbertMarieM,
pubmed-author:RollandFrédéricF,
pubmed-author:SaiaghSorayaS,
pubmed-author:SalotSamuelS,
pubmed-author:TiollierJérômeJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1599-609
|
|
pubmed:meshHeading |
pubmed-meshheading:18301889-Adult,
pubmed-meshheading:18301889-Aged,
pubmed-meshheading:18301889-Antineoplastic Agents,
pubmed-meshheading:18301889-Carcinoma, Renal Cell,
pubmed-meshheading:18301889-Combined Modality Therapy,
pubmed-meshheading:18301889-Disease Progression,
pubmed-meshheading:18301889-Female,
pubmed-meshheading:18301889-Humans,
pubmed-meshheading:18301889-Immunotherapy,
pubmed-meshheading:18301889-Interleukin-2,
pubmed-meshheading:18301889-Kidney Neoplasms,
pubmed-meshheading:18301889-Lymphocyte Count,
pubmed-meshheading:18301889-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:18301889-Male,
pubmed-meshheading:18301889-Maximum Tolerated Dose,
pubmed-meshheading:18301889-Middle Aged,
pubmed-meshheading:18301889-Prognosis,
pubmed-meshheading:18301889-Receptors, Antigen, T-Cell, gamma-delta,
pubmed-meshheading:18301889-Survival Rate,
pubmed-meshheading:18301889-T-Lymphocytes
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
|
|
pubmed:affiliation |
Department of Medical Oncology, Centre René Gauducheau, Nantes-Saint-Herblain, France. j-bennouna@nantes.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
